Page 58 - GALENIKA MEDICAL JOURNAL

7. Mulè G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri 29. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al;
D, et al. Subclinical Kidney Damage in Hypertensive Patients: Collaborative Study Group. Renoprotective effect of the angiotensin-
A Renal Window Opened on the Cardiovascular System. Focus receptor antagonist irbesartan in patients with nephropathy
on Microalbuminuria. Adv Exp Med Biol. 2017;956:279-306. due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60.
8. Redon J. Renal protection by antihypertensive drugs: insights from 30. Yasuda T, Endoh M, Suzuki D, Yoshimura A, Ideura T, Tamura
microalbuminuria studies. J Hypertens. 1998;16(12 Pt 2):2091-100. K, et al; KVT Study Group. Effects of valsartan on progression
of kidney disease in Japanese hypertensive patients with
9. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II advanced, predialysis, chronic kidney disease: Kanagawa
type 1 receptor blockers reduce urinary oxidative stress markers in Valsartan Trial (KVT). Hypertens Res. 2013;36(3):240-6.
hypertensive diabetic nephropathy. Hypertension. 2006;47(4):699-705.
31. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T; ALICE
10. Rizos EC, Agouridis AP, Elisaf MS. Aliskiren in patients with diabetes: (All-Literature Investigation of Cardiovascular Evidence) Group.
a systematic review. Curr Vasc Pharmacol. 2012;10(2):140-6. Effects of telmisartan on proteinuria or albuminuria: a meta-
11. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, analysis of randomized trials. Int J Cardiol. 2013;167(4):1443-9.
Solomon SD, et al; ALTITUDE Investigators. Cardiorenal end points in a 32. Hamamoto Y, Koshiyama H. ROADMAP and ORIENTAL Trials: the
trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204-13. Re-emergence of J-Curve Ghost? Jpn Clin Med. 201;2:25-8.
12. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal 33. Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti
renin-angiotensin system: from physiology to the pathobiology of G, et al. Comparative efficacy and safety of blood pressure-
hypertension and kidney disease. Pharmacol Rev. 2007; 59:251–87. lowering agents in adults with diabetes and kidney disease: a
13. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison- network meta-analysis. Lancet. 2015;385(9982):2047-56.
Bernard LM, Mitchell KD. Paracrine regulation of the renal 34. Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and
microcirculation. Physiol Rev. 1996; 76:425–536. prevention of gout. Am Fam Physician. 2014;90(12):831-6.
14. Ito S. Cardiorenal connection in chronic kidney 35. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-
disease. Clin Exp Nephrol. 2012; 16:8–16. dependent mode of interaction of angiotensin II receptor blockers
15. Imanishi M, Yoshioka K, Konishi Y, Okumura M, Okada N, Sato with uric acid transporter. J Pharmacol Exp Ther. 2007;320(1):211-7.
T, et al Glomerular hypertension as one cause of albuminuria in 36. Dézsi CA. The different therapeutic choices with ARBs. Which one
type II diabetic patients. Diabetologia. 1999;42(8):999-1005. to give? When? Why? Am J Cardiovasc Drugs. 2016;16(4):255-66.
16. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et 37. Bahnassi A, Abuirmeileh A, Abuirmeileh A. The hypotensive
al. Temporary angiotensin II blockade at the prediabetic and uricosuric effect of valsartan compared to losartan
stage attenuates the development of renal injury in type in gout patients. J Health Spec 2016;4:52-5.
2 diabetic rats. J Am Soc Nephrol. 2005;16(3):703-11.
38. Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of
17. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, irbesartan on serum uric acid levels in patients with
Danser AH. Hypertension: renin-angiotensin-aldosterone hypertension and diabetes. Clin Pharmacol. 2014;6:79-86.
system alterations. Circ Res. 2015;116(6):960-75.
39. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients
18. Elder Dalpoas S, Samal L, Pham PA. ARBs. Johns Hopkins Diabetes at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
Guide. 2017. https://www.hopkinsguides.com/hopkins/view/Johns_
Hopkins_Diabetes_Guide/547012/all/ARBs. Accessed February 6, 2022. 40. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA,
Duckworth W, et al; VA NEPHRON-D Investigators. Combined
19. Del Fiorentino A, Cianchetti S, Celi A, Dell'Omo G, Pedrinelli angiotensin inhibition for the treatment of diabetic
R. The effect of angiotensin receptor blockers on C-reactive nephropathy. N Engl J Med. 2013;369(20):1892-903.
protein and other circulating inflammatory indices in
man. Vasc Health Risk Manag. 2009;5(1):233-42. 41. Li EC, Heran BS, Wright JM. Angiotensin converting enzyme (ACE)
inhibitors versus angiotensin receptor blockers for primary
20. Zandbergen AA, Baggen MG, Lamberts SW, Bootsma AH, de hypertension. Cochrane Database Syst Rev. 2014;2014(8):CD009096.
Zeeuw D, Ouwendijk RJ. Effect of losartan on microalbuminuria
in normotensive patients with type 2 diabetes mellitus. A 42. Chen R, Suchard MA, Krumholz HM, Schuemie MJ, Shea S, Duke J, et al.
randomized clinical trial. Ann Intern Med. 2003;139(2):90-6. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-
Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers:
21. Agha A, Amer W, Anwar E, Bashir K. Reduction of A Multinational Cohort Study. Hypertension. 2021;78(3):591-603.
microalbuminuria by using losartan in normotensive patients
with type 2 diabetes mellitus: A randomized controlled 43. Xu R, Sun S, Huo Y, Yun L, Huang S, Li G, et al. Effects of ACEIs Versus
trial. Saudi J Kidney Dis Transpl. 2009;20(3):429-35. ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-
Analysis of Randomized Trials. Medicine (Baltimore). 2015;94(39):e1560.
22. Lozano JV, Llisterri JL, Aznar J, Redon J; Spanish Working Group.
Losartan reduces microalbuminuria in hypertensive microalbuminuric 44. Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, et al. Effects of
type 2 diabetics. Nephrol Dial Transplant. 2001;16 Suppl 1:85-9. Angiotensin-Converting Enzyme Inhibitors and Angiotensin II
Receptor Blockers on All-Cause Mortality and Renal Outcomes
23. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With in Patients with Diabetes and Albuminuria: a Systematic Review
VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction and Meta-Analysis. Kidney Blood Press Res. 2018;43(3):768-79.
with valsartan in patients with type 2 diabetes mellitus: a blood
pressure-independent effect. Circulation. 2002;106(6):672-8. 45. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-
Angiotensin System Inhibitors and Kidney and Cardiovascular
24. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et Outcomes in Patients With CKD: A Bayesian Network Meta-analysis
al; INNOVATION Study Group. Microalbuminuria reduction with of Randomized Clinical Trials. Am J Kidney Dis. 2016;67(5):728-41.
telmisartan in normotensive and hypertensive Japanese patients
with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: 46. Bakris GL. Protecting renal function in the hypertensive patient:
Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic clinical guidelines. Am J Hypertens. 2005;18(4 Pt 2):112S-119S.
Nephropathy (INNOVATION) study. Hypertens Res. 2008;31(4):657-64.
47. Hoyer J, Schulte KL, Lenz T. Clinical pharmacokinetics of
25. Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH. Effect of angiotensin converting enzyme (ACE) inhibitors in renal
losartan versus candesartan on uric acid, renal function, and failure. Clin Pharmacokinet. 1993;24(3):230-54.
fibrinogen in patients with hypertension and hyperuricemia
associated with diuretics. Am J Hypertens. 2006;19(2):208-13.
26. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al;
ROADMAP Trial Investigators. Olmesartan for the delay or prevention of
microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907-17.
Konflikt interesa: Nema
27. Cetinkalp SS, Karadeniz MM, Erdogan MA, Ozgen GA, Yilmaz CO. Short-
term effects of irbesartan treatment on microalbuminuria in patients Primljeno: 10. 02. 2022.
with normotensive type 2 diabetes. Saudi Med J. 2008;29(10):1414-8.
Prihvaćeno: 21. 04. 2022.
28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Onlajn: 30. 06. 2022.
Parving HH, et al; RENAAL Study Investigators. Effects of losartan
on renal and cardiovascular outcomes in patients with type 2
diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9.
58 DOI: 10.5937/Galmed2202053S